Cases – Page 49 – ClaimsFiler

Recent Security Class Actions

Rosetta Stone (NYSE: RST)

According to the Complaint, Rosetta Stone’s language division uses advanced digital technology to help all types of learners read, write, and speak more than thirty languages. Lexia Learning, the Company’s literacy education division, is a leader in the literacy education space. Lexia Learning helps students build fundamental reading skills through its instruction and assessment programs.

According to the Complaint, Garrison Capital Inc. is an externally managed, non-diversified, closed-end management investment company that has elected to be treated as a business development company under the Investment Company Act of 1940. The Company is managed by its investment adviser, Garrison Capital Advisers LLC, an affiliate of Garrison Investment Group, and a registered investment adviser under the Investment Advisers Act of 1940, which provides the resources and expertise of the investment professionals at Garrison Investment Group.

According to the Complaint, Wrap Technologies, Inc. purports to develop security products for law enforcement and security personnel, including the BolaWrap 100, a hand-held remote restraint device that discharges an eight-foot bola style Kevlar tether to entangle a subject at a range of 10-25 feet.

According to the Complaint, Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered community commercial bank that was founded in 1864. Dime Community Bank is headquartered in Brooklyn, New York and operates twenty-eight banking offices located throughout Brooklyn, Queens, the Bronx, Nassau, and Suffolk Counties, New York.

According to the Complaint, Akcea Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases.

According to the Complaint, NextCure, Inc. is a clinical-stage biopharmaceutical company striving to discover and develop novel, first-in-class immunomedicine to treat cancer and other immune-related diseases by restoring normal immune function.

According to the Complaint, Fluidigm Corporation manufactures and markets products and services that are used by researchers to study health and disease, identify biomarkers, and accelerate the development of therapies. The Company uses proprietary CyTOF and microfluidics technologies to develop its end-to-end solutions.

According to the Complaint, Odonate Therapeutics, Inc. is a pharmaceutical company that develops therapeutics for the treatment of cancer. The Company is focused on developing tesetaxel, an orally administered chemotherapy agent.

According to the Complaint, Nikola Corporation purports to operate as an integrated zero emissions transportation systems provider which designs and manufactures battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen fueling station infrastructure.

According to the Complaint, Colony Credit Real Estate, Inc. is a commercial real estate (“CRE”) credit real estate investment trust (“REIT”) that purports to manage a diversified portfolio of CRE senior mortgage loans, mezzanine loans, preferred equity, debt securities, and net leased properties predominantly in the U.S.

According to the Complaint, Livongo Health, Inc. has created a unified platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications across multiple chronic conditions for its members.

YayYo, Inc. (NASDAQ: YAYO)

According to the Complaint, YayYo, Inc. purports to, through its subsidiaries, operate an online peer-to-peer booking platform that rents standard passenger vehicles to self-employed ridesharing drivers and manages a fleet of standard passenger vehicles to be rented directly to drivers in the ridesharing economy.

According to the Complaint, Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform.

According to the Complaint, Momenta Pharmaceuticals, Inc.is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immunemediated diseases.

We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.

OK